Hyderabad-based Bio-tech Firm Transcell Biologics Secures Undisclosed Investment
Hyderabad, India – Transcell Biologics, a leading biotech company specializing in stem cell technology, has announced that it has raised an undisclosed amount of investment from Boston-based venture capital firm Quantiphi and IAN Group. The investment is intended to accelerate the expansion of the company’s client base and implementation of its Digital Animal Replacement Technology (DART) as an enterprise solution for the global bio and pharmaceutical industry.
Founded in 2009 by Subadra Dravida, Transcell Biologics has established itself as a pioneer in maximizing stem cell yield while retaining pluripotency and functionality. The company has developed a proprietary process that has diversified its applications for stem cell technologies.
DART, a pioneering technology developed by Transcell Biologics, combines human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to streamline and automate bioassay processes, producing statistically compliant reports. The solution is designed to test safety and efficacy concerns surrounding drugs and vaccines meant for human consumption, providing a more efficient and effective alternative to traditional animal testing methods.
The adoption of DART has gained significant traction in the Indian market, with biopharmaceutical companies adopting its enterprise solution in their high-impact programs. With the fresh investment, Transcell Biologics aims to expand its client base in the USA, Europe, and Japan, further establishing its presence in the global bio and pharmaceutical industry.
Key Highlights:
- Transcell Biologics raises an undisclosed amount of investment from Quantiphi and IAN Group
- Investment to be used for expanding client base and implementing DART as an enterprise solution
- DART provides a digital platform for animal-free testing methods using hMPS and AI/ML technology
- Solution designed to streamline and automate bioassay processes and produce statistically compliant reports
- Adoption of DART has gained traction in Indian markets, with plans to expand globally
